124020_2_supp_2666378_nc45vw
1
Supplemental Table 2 Patient information, clinical response and urinary MMP levels evaluated in the MFG4991g phase I study Patie nt no. pro MMP-10 (ng/mL) MMP-1 (ng/ mL) MMP-3 (ng/ mL) MMP-9 (ng/mL) Best response Dose (mg/kg) Tumor origin PFS (Month ) <LOD <LLOQ 0.06 3.97 PD 2 anal 1.4 102 <LOD <LOD 0.02 11.43 PD 2 STS 1.5 104 <LOD <LLOQ 0.20 1.20 SD 2 thyroid 1.7 105 <LOD <LLOQ 0.12 0.09 PD 2 esophageal 1.8 106 <LOD <LLOQ 0.12 4.36 SD 4,8,15,3 0 bladder cancer 9 107 <LOD <LLOQ 0.06 2.35 PD 4 ovarian 1 108 <LOD <LLOQ 0.04 0.12 PD 4 adrenal 1.9 109 0.05 0.06 0.63 58.58 PD 8 CRC 1.1 110 <LOD 2.74 0.24 1803.63 SD 8 bladder cancer 3.3 111 <LOD <LLOQ 0.03 0.18 SD 8 carcinoid 7.3 112 <LOD 0.01 0.05 0.22 PD 8 SCCHN 1.3 113 0.01 0.00 0.32 0.00 PD 15 CRC 1.1 114 0.01 0.02 0.05 223.50 PD 15 CRC 1.2 115 0.01 <LLOQ 0.00 19.03 PD 15 mucoepiderm oid 1.6 116 0.01 0.78 1.50 52.35 PD 15 bladder cancer 1.7 117 0.04 1.01 1.18 324.92 PD 15 bladder cancer 0.8 118 0.01 <LLOQ 0.02 2.16 SD 15 adenoid cysitc 12.3 119 0.01 <LLOQ 0.01 3.55 SD 30 carcinoid 5.4 120 0.01 <LLOQ 0.01 26.70 PD 30 esophageal 1.7 121 0.12 4.37 0.48 418.00 SD 30 bladder cancer 5.8 122 0.09 0.14 0.81 54.26 PD 30 bladder cancer 1.6 123 0.02 0.16 0.12 13.50 PD 30 bladder cancer 0.2 124 0.02 <LLOQ 0.03 0.59 SD 30 adenoid cystic 3.7 125 0.01 <LOD 0.02 0.01 SD 30 bladder cancer 5.7 126 0.12 0.55 0.03 0.33 SD 30 bladder cancer 7.3 127 1.17 7.58 0.18 1.79 PD 30 bladder cancer 0.6 Note: Patients 104 and 118 censored at the last non-PD tumor assessment All bladder cancer patients have distant metastatic lesions.
-
Upload
sharon-kelly -
Category
Documents
-
view
17 -
download
2
description
Supplemental Table 2 Patient information, clinical response and urinary MMP levels evaluated in the MFG4991g phase I study. - PowerPoint PPT Presentation
Transcript of 124020_2_supp_2666378_nc45vw
Supplemental Table 2 Patient information, clinical response and urinary MMP levels evaluated in the MFG4991g phase I study
Patient no.
pro MMP-10
(ng/mL)
MMP-1(ng/mL)
MMP-3(ng/mL)
MMP-9(ng/mL)
Best response
Dose (mg/kg)
Tumor originPFS
(Month)
<LOD <LLOQ 0.06 3.97 PD 2 anal 1.4102 <LOD <LOD 0.02 11.43 PD 2 STS 1.5104 <LOD <LLOQ 0.20 1.20 SD 2 thyroid 1.7105 <LOD <LLOQ 0.12 0.09 PD 2 esophageal 1.8
106 <LOD <LLOQ 0.12 4.36 SD 4,8,15,30 bladder cancer 9107 <LOD <LLOQ 0.06 2.35 PD 4 ovarian 1108 <LOD <LLOQ 0.04 0.12 PD 4 adrenal 1.9109 0.05 0.06 0.63 58.58 PD 8 CRC 1.1
110 <LOD 2.74 0.24 1803.63 SD 8 bladder cancer 3.3111 <LOD <LLOQ 0.03 0.18 SD 8 carcinoid 7.3112 <LOD 0.01 0.05 0.22 PD 8 SCCHN 1.3113 0.01 0.00 0.32 0.00 PD 15 CRC 1.1114 0.01 0.02 0.05 223.50 PD 15 CRC 1.2
115 0.01 <LLOQ 0.00 19.03 PD 15mucoepidermo
id 1.6
116 0.01 0.78 1.50 52.35 PD 15 bladder cancer 1.7
117 0.04 1.01 1.18 324.92 PD 15 bladder cancer 0.8
118 0.01 <LLOQ 0.02 2.16 SD 15 adenoid cysitc 12.3119 0.01 <LLOQ 0.01 3.55 SD 30 carcinoid 5.4120 0.01 <LLOQ 0.01 26.70 PD 30 esophageal 1.7
121 0.12 4.37 0.48 418.00 SD 30 bladder cancer 5.8
122 0.09 0.14 0.81 54.26 PD 30 bladder cancer 1.6
123 0.02 0.16 0.12 13.50 PD 30 bladder cancer 0.2
124 0.02 <LLOQ 0.03 0.59 SD 30 adenoid cystic 3.7
125 0.01 <LOD 0.02 0.01 SD 30 bladder cancer 5.7
126 0.12 0.55 0.03 0.33 SD 30 bladder cancer 7.3
127 1.17 7.58 0.18 1.79 PD 30 bladder cancer 0.6
Note: Patients 104 and 118 censored at the last non-PD tumor assessmentAll bladder cancer patients have distant metastatic lesions.
